Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.00
-0.86 (-3.78%)
At close: Mar 6, 2026, 4:00 PM EST
22.00
0.00 (0.02%)
After-hours: Mar 6, 2026, 4:04 PM EST
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 35.33, with a low estimate of 24 and a high estimate of 65. The average target predicts an increase of 60.63% from the current stock price of 22.00.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Pacira BioSciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 1 | 2 | 2 | 1 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 6 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +72.77% | Jan 9, 2026 |
| Needham | Needham | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +36.39% | Jan 9, 2026 |
| Barclays | Barclays | Hold Initiates $27 | Hold | Initiates | $27 | +22.76% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +72.77% | Nov 17, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +27.30% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
797.40M
from 726.41M
Increased by 9.77%
Revenue Next Year
874.81M
from 797.40M
Increased by 9.71%
EPS This Year
3.07
from 0.16
Increased by 1,843.84%
EPS Next Year
3.83
from 3.07
Increased by 24.67%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 848.5M | 944.5M | |||
| Avg | 797.4M | 874.8M | |||
| Low | 743.1M | 790.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 16.8% | 18.4% | |||
| Avg | 9.8% | 9.7% | |||
| Low | 2.3% | -0.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 4.03 | 4.67 | |||
| Avg | 3.07 | 3.83 | |||
| Low | 2.45 | 3.08 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2,453.3% | 52.3% | |||
| Avg | 1,843.8% | 24.7% | |||
| Low | 1,454.1% | 0.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.